Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Idar, Lygren"'
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150191 (2016)
Ingestion of AndoSan™, based on the mushroom Agaricus blazei Murill, has previously been shown to exhibit anti-inflammatory effects because of reduction of pro-inflammatory cytokines in healthy individuals and patients with ulcerative colitis. In t
Externí odkaz:
https://doaj.org/article/6d76322ec4d747aa9e4249d455d25964
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159288 (2016)
Ingestion of AndoSanTM, based on the mushroom Agaricus blazei Murill, has previously shown an anti-inflammatory effect through reduction of pro-inflammatory cytokines in healthy individuals and patients with Crohn's disease (CD). In this randomized s
Externí odkaz:
https://doaj.org/article/7764841ef0bf4148a793b748bbe2f7eb
Publikováno v:
Scandinavian Journal of Immunology. 84:323-331
Ingestion of the Agaricus blazei Murill-based mushroom extract AndoSan™ has been shown in randomized placebo-controlled studies to improve symptoms in Crohn's disease (CD) and ulcerative colitis (UC) and also fatigue and quality of life in the latt
Autor:
Idar Lygren, Jonas Koch, Severine Vermeire, Geert DʼHaens, Filip Baert, Jørgen Jahnsen, Inger Camilla Solberg, Edouard Louis, Fernand Fontaine, Tore Grimstad, Roald Torp, Lars Normann Karlsen, Olivier Dewit, D Staessen, Martine De Vos, Jean-Claude R J Coche, Fazia Mana, Guy Lambrecht, Vinciane Muls, Maja Noman, Thomas de Lange, Bert Vander Cruyssen, Philippe M R Potvin, Gert A. Van Assche, Pieter Hindryckx, André Van Gossum, Magne Henriksen, Cool M, Jacques Belaiche, Jo G P Vandervoort, Jean-Marc Maisin, Denis Franchimont, Eirik Kittang, Bart Neuville, Arnaud Collard, Philippe Van Hootegem, Tom G. Moreels
Publikováno v:
Inflammatory bowel diseases
Inflammatory bowel diseases, 19(10), 2111-2117. John Wiley and Sons Inc.
Inflammatory bowel diseases, 19(10), 2111-2117. John Wiley and Sons Inc.
Background:This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab maintenance therapy.Methods:This prospective multicenter study enrolled adult pa
Autor:
Bjørn Moum, I.C. Solberg, Marte Lie Høivik, Jørgen Jahnsen, Idar Lygren, Milada Cvancarova, Tomm Bernklev
Publikováno v:
Journal of Crohn's and Colitis. 6:441-453
Background and aims Data on the long-term effects of Crohn's disease (CD) on health-related quality of life (HRQoL) is scarce. We aimed to determine the HRQoL in CD patients 10 years after disease onset, to compare the results to the general populati
Publikováno v:
Scandinavian Journal of Immunology. 73:66-75
An immunomodulatory extract (AndoSan™) based on the medicinal mushroom Agaricus blazei Murill (AbM) has shown to reduce blood cytokine levels in healthy volunteers after 12 days' ingestion, pointing to an anti-inflammatory effect. The aim was to st
Autor:
Ingebjørg Seljeflot, Mette R. Holthe, Per Wiik Johansen, Anne-Marie Siebke Trøseid, Odd Brørs, Per-Morten Sandset, Marianne K. Kringen, Idar Lygren, Sigrid Narum
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 108:194-201
Gastrointestinal (GI) bleeding may be caused by a constitutive bleeding disposition or drug-induced inhibition of hemostasis. Platelet function in patients with ongoing GI bleeding is unknown. The aim of this study was to investigate platelet functio
Publikováno v:
Tidsskrift for Den norske legeforening. 130:1135-1139
Background Many drugs increase the risk for gastroduodenal ulcer bleeding. The aim of this study was to investigate Helicobacter pylori infection and drug use in patients who had gastroduodenal ulcer bleeding in 2002 or 2007, and possible differences
Autor:
Geir Aamodt, Jørgen Jahnsen, May-Bente Bengtson, Camilla Solberg, Bjørn Moum, Idar Lygren, Jostein Sauar, Morten H. Vatn
Publikováno v:
Journal of Crohn's and Colitis. 3:92-99
Background and aims To explore the change in risk among 1st degree relatives of ulcerative colitis (UC) and Crohn's disease (CD) for development of concordant disease in an incidence cohort followed for ten years. Furthermore, we wanted to compare fa
Publikováno v:
Scandinavian Journal of Gastroenterology. 43:217-222
The mortality rate associated with bleeding duodenal ulcer disease is about 10%. Primary endoscopic hemostasis is successful in over 90% of patients, but in 15-25%, the bleeding cannot be controlled endoscopically or the patient rebleeding, requiring